511 related articles for article (PubMed ID: 14754694)
1. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
2. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
[TBL] [Abstract][Full Text] [Related]
3. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
4. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
[TBL] [Abstract][Full Text] [Related]
5. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens.
Utian WH; Lederman SA; Williams BM; Vega RY; Koltun WD; Leonard TW
Obstet Gynecol; 2004 Feb; 103(2):245-53. PubMed ID: 14754691
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
[TBL] [Abstract][Full Text] [Related]
7. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
8. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome.
Simon JA; Stevens RE; Ayres SA; Phelps KV
Climacteric; 2001 Mar; 4(1):19-27. PubMed ID: 11379374
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial.
Cravioto MD; Durand-Carbajal M; Jiménez-Santana L; Lara-Reyes P; Seuc AH; Sánchez-Guerrero J
Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1654-63. PubMed ID: 22127965
[TBL] [Abstract][Full Text] [Related]
10. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
11. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
[TBL] [Abstract][Full Text] [Related]
14. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
15. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.
Nevitt MC; Felson DT; Williams EN; Grady D
Arthritis Rheum; 2001 Apr; 44(4):811-8. PubMed ID: 11315920
[TBL] [Abstract][Full Text] [Related]
16. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
17. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
Archer DF;
Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
[TBL] [Abstract][Full Text] [Related]
20. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial.
Liu JH; Reape KZ; Hait HI
Obstet Gynecol; 2012 Jan; 119(1):78-84. PubMed ID: 22183214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
